Aerosolized bechlometasone dipropionate (BDP) delivered via TNI® vesicles: a new approach for the treatment of asthmatic and COPD patients

C. Terzano, M. Carafa (Roma, Chieti, Italy)

Source: Annual Congress 2002 - Lung disposition clinical outcomes: effect of delivery device
Session: Lung disposition clinical outcomes: effect of delivery device
Session type: Thematic Poster Session
Number: 3132
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Terzano, M. Carafa (Roma, Chieti, Italy). Aerosolized bechlometasone dipropionate (BDP) delivered via TNI® vesicles: a new approach for the treatment of asthmatic and COPD patients. Eur Respir J 2002; 20: Suppl. 38, 3132

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Extrafine beclomethasone dipropionate aerosol therapy shows promising improved effect in treatment of children with stable asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 378s
Year: 2004

Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

A comparison of salmeterol xinafoate (SX) plus beclomethasone dipropionate (BDP) and theophylline (Theo) plus BDP in the treatment of moderate chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005

Protective effect of inhaled beclomethasone dipropionate (BDP) in asthmatic patients with exercise-induced bronchoconstriction (EIB)
Source: Eur Respir J 2002; 20: Suppl. 38, 306s
Year: 2002

HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005

Equivalence of beclomethasone dipropionate (1000 μg/die) and budesonide (800 μg/die) in patients with moderate asthma on clinical findings and inflammatory markers
Source: Eur Respir J 2001; 18: Suppl. 33, 97s
Year: 2001

Acceptability and efficacy of beclomethasone dipropionate (Béclojet HFA®) and fluticasone dipropionate (Flixotide HFA®, FDP) associated with the Volumatic® spacer in adults with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Inhalation of beclomethason dipropionate spray compared with theophilline as primary treatment for chronic mild-to-moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone
Source: Eur Respir J 2003; 22: Suppl. 45, 410s
Year: 2003

Efficacy and safety of the new beclomethasone dipropionate/formoterol combination (HFA MDI) vs. budesonide/formoterol (DPI) in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 434s
Year: 2006

Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Nebulized beclomethasone dipropionate is as effective and as well tolerated than nebulized budesonide to prevent asthma exacerbations in infants
Source: Eur Respir J 2001; 18: Suppl. 33, 122s
Year: 2001

Use of step-down design to study dose comparability of budesonide (B) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 534s
Year: 2003

Salmeterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007


Late Breaking Abstract - Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021